Saturday 7 November 2026
Export LNTH’s income statement to Excel — free account
Lantheus Holdings, Inc.
LNTH Healthcare Drug Manufacturers Specialty & Generic
Lantheus Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.5 billion, up 0.50% from fiscal 2024.
- Revenue
- +1.54%
- EPS
- −16.4%
- Free cash flow
- +7.71%
- Total debt
- +0.52%
Quarter to September 2026, against a year earlier
100.65
0.05
−0.05%
Follow LNTH
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
5 | 5 | 5 | 7 |
| 21.45% | 23.48% | 22.21% | 21.81% | ||
| 11.10% | 12.68% | 12.15% | 11.41% | ||
ROIC |
14.94% | 14.12% | 14.65% | 14.62% | |
Return on Tangible Assets |
31.98% | 36.39% | 32.59% | 29.10% | |
Average Days of Receivables |
88.56 | 84.31 | 83.04 | 80.77 | |
Free Cash Flow per Share |
5.25 | 5.90 | 6.03 | 6.02 | |
Free Cash Flow |
354.05 | 382.11 | 392.83 | 393.09 | |
Capital Expenditures |
(36.09) | (25.60) | (19.97) | (16.39) | |
| Other line items | |||||
Cash ROIC |
17.54% | 16.75% | 15.86% | 15.05% | |
Accounts Receivable Turnover |
4.38 | 4.38 | 4.51 | 4.29 | |
Accounts Payable Turnover |
15.48 | 13.47 | 13.94 | 10.62 | |
Inventory Turnover |
9.04 | 9.37 | 10.36 | 9.59 | |
Average Days of Payables |
26.12 | 27.40 | 28.31 | 28.77 | |
Days of Inventory on Hand |
39.37 | 36.64 | 33.86 | 38.73 | |
Tax Rate |
(0.26) | (0.25) | (0.24) | (0.21) | |
Research and Development Expense of Revenue |
11.50% | 11.67% | 11.12% | 13.94% | |
Selling, General and Administrative Expense of Revenue |
29.44% | 30.06% | 29.60% | 28.70% | |
Share Based Compensation of Revenue |
5.55% | 5.20% | 5.02% | 4.83% | |
Interest Coverage |
15.74 | 14.64 | 15.26 | 14.70 | |
Operating CF/Net income |
1.67 | 1.46 | 1.50 | 1.52 | |
Depreciation/Fixed assets |
0.46 | 0.53 | 0.61 | 0.64 | |
Capex/Depreciation |
(0.48) | (0.31) | (0.21) | (0.17) | |
Revenue per Share |
22.84 | 23.88 | 23.88 | 23.92 | |
Operating CF per Share |
5.78 | 6.30 | 6.34 | 6.27 | |
Capex per Share |
(0.53) | (0.40) | (0.31) | (0.25) | |
Capex to Sales |
0.02 | 0.02 | 0.01 | 0.01 |
Columns are period end dates · fundamentals updated 6 Nov 2026